Combined LABA/steroid inhaler added to Easyhaler range

Fobumix Easyhaler 320/9 (budesonide/formoterol) is a breath-actuated dry-powder inhaler licensed for the treatment of asthma and COPD.

Fobumix Easyhaler is not recommended for use in children and adolescents under 18 years. | ORION PHARMA
Fobumix Easyhaler is not recommended for use in children and adolescents under 18 years. | ORION PHARMA

Each delivered dose from the Fobumix Easyhaler contains budesonide 320 micrograms and formoterol fumarate dihydrate 9 micrograms. This corresponds to that received from other budesonide/formoterol combination products which have a metered dose of 400 microgram budesonide and 12 micrograms formoterol but similiar delivered doses to Fobumix.

Fobumix is licensed for the regular treatment of asthma where use of a long acting β2-agonist and an inhaled corticosteroid is appropriate and for the symptomatic treatment of COPD with a FEV1 <70% predicted normal and a history of repeated exacerbations despite regular therapy with long acting bronchodilators.

The recommended dose of Fobumix for asthma is one inhalation twice daily increasing to two inhalations twice daily if necessary. The dose should be titrated to the lowest effective dose, which could include Fobumix Easyhaler given once daily. Other lower strengths of Fobumix Easyhaler are not yet available.

The recommended dose of Fobumix for COPD is one inhalation twice daily.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in